Rocket Doctor Announces Granting of RSUs and Options and a Change of CFO
Rhea-AI Summary
Rocket Doctor AI (CSE: AIDR | OTC: AIRDF) announced a management change and equity awards on Dec 5, 2025. Effective Dec 8, 2025, Christopher Cherry will become Interim Chief Financial Officer, replacing David Worner; Mr. Cherry currently serves as Chair of the Audit Committee.
The company granted an aggregate 579,028 stock options exercisable at $0.84 per share with terms of three or five years, and 931,112 restricted share units with terms of two to five years, to executives, directors and consultants. Awards are issued under the company’s share compensation plans and are subject to vesting conditions.
Positive
- Interim CFO appointment effective Dec 8, 2025
- Interim CFO is current Chair of the Audit Committee
- Granted 579,028 options at $0.84 exercise price
- Issued 931,112 RSUs with 2–5 year terms
Negative
- CFO transition may cause short-term finance leadership disruption
News Market Reaction
On the day this news was published, AIRDF declined 5.74%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
No peer stocks or sector momentum data are provided, suggesting the move reflects stock-specific factors rather than a broader sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 08 | AI partnership | Positive | -5.7% | AI-powered CDSS pilot with CAN Health Network and Health Cities in Alberta. |
| Dec 05 | Mgmt & equity awards | Neutral | -5.7% | Interim CFO appointment plus stock option and RSU grants to insiders. |
| Dec 04 | Education partnership | Positive | +2.0% | Strategic partnership with TMU to support clinical education on digital platform. |
| Dec 02 | Q3 results & growth | Positive | +1.2% | Q3 revenue growth, high gross margin, financing and U.S. payer expansion. |
| Nov 26 | Conference exposure | Positive | +9.6% | CEO presentations at Google Accelerator Alumni and Heal.LA Demo Day. |
Recent news has generally been positive, with three events showing price gains and one notable negative divergence where positive AI partnership news coincided with a selloff.
This announcement follows a series of growth- and visibility-focused updates. On Nov 26, 2025, a positive speaking and accelerator exposure event saw a 9.63% gain. Q3 2025 results on Dec 2 highlighted revenue of $529,123 and gross margin of 88%, with a 1.2% rise. A TMU education partnership on Dec 4 coincided with a 1.96% increase. However, an AI CDSS partnership and this CFO/equity award news on Dec 5–8 both saw -5.74% moves, showing mixed reactions.
Market Pulse Summary
The stock moved -5.7% in the session following this news. A negative reaction despite largely routine compensation and a planned CFO transition would fit prior divergence where positive AI partnership news coincided with a -5.74% move. The stock traded about 19.3% below its 52-week high before this update, so sentiment was already cautious. Added equity awards can raise dilution concerns, and past mixed reactions to otherwise constructive news suggest that confidence in execution and capital structure has been an important factor.
Key Terms
stock options financial
vesting conditions financial
AI-generated analysis. Not financial advice.
Vancouver, BC, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Rocket Doctor AI Inc.'s (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) (“Rocket Doctor AI”) announces that Christopher Cherry shall assume the role of Interim Chief Financial Officer, to replace David Worner, effective December 8, 2025.
Mr. Cherry is currently the Company’s Chair of the Audit Committee.
The Company thanks Mr. Worner for his services to the Company and wishes him all the best in future endeavours.
Additionally, the Company has granted an aggregate 579,028 stock options, exercisable at
About Rocket Doctor AI Inc.
Rocket Doctor AI Inc. delivers physician-built, AI-powered solutions designed to make high-quality healthcare accessible throughout the entire patient journey. A cornerstone of the company’s proprietary technology is the Global Library of Medicine (GLM), a clinically validated decision support system developed with input from hundreds of physicians worldwide.
Alongside the GLM is Rocket Doctor Inc, and its AI-powered digital health platform and marketplace. Having helped empower over 300 MDs to provide care to more than 700,000 patient visits, our proprietary technology software and systems enable doctors to independently launch and manage their own virtual or hybrid in-person practices - improving efficiency, restoring autonomy to MDs, and expanding patient access to care.
By reducing administrative burdens and ensuring greater consistency in care, our technology creates more time for meaningful physician-patient interactions. We are committed to reaching underserved, rural, and remote communities in Canada who often lack access to family doctors and supporting patients on Medicaid and Medicare in the United States. With advanced AI, large language models, and connected medical devices, Rocket Doctor AI is redefining modern healthcare - making it more scalable, equitable, and patient-centered.
To learn more about Rocket Doctor AI Inc’s products and services, contact:
www.rocketdoctor.ai or email: info@rocketdoctor.ai
FOR ADDITIONAL INFORMATION, CONTACT:
Dr. Essam Hamza, CEO, Rocket Doctor AI
essam.hamza@rocketdoctor.ai
Dr. Bill Cherniak, CEO, Rocket Doctor Inc.
bill@rocketdoctor.io
For media inquiries, contact: media@rocketdoctor.ai
Call: +1 (778) 819 8321
Cautionary Statements
This news release contains forward-looking statements relating to the future operations of Rocket Doctor AI Inc. and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Offering, the use of proceeds of the Offering, the filing of a Prospectus Supplement and future plans and objectives of Rocket Doctor AI Inc., are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Rocket Doctor AI Inc.'s expectations include other risks detailed from time to time in the filings made by Rocket Doctor AI Inc. with securities regulators.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Rocket Doctor AI Inc. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Rocket Doctor AI Inc. will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law.
FAQ
When does Christopher Cherry become Interim CFO of Rocket Doctor (AIRDF)?
How many stock options did Rocket Doctor (AIRDF) grant and at what price?
What are the terms of the stock options and RSUs granted by Rocket Doctor (AIRDF)?
How many restricted share units did Rocket Doctor (AIRDF) issue?
Who did Rocket Doctor (AIRDF) replace as CFO and was any reason given?
